Recent News


Recent News

August 13, 2018

Tessa Therapeutics featured on CNBC Capital Connection

Tessa’s CFO, Desmond Lim spoke on Tessa’s plans for the future and the promise of Virus-Specific T Cell (VST) cancer immunotherapy. Watch the interview here.


JAMA Oncol. 2017 Aug 1;3(8):1094-1101. doi: 10.1001/jamaoncol.2017.0184.

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial

View Citation

Ahmed, Nabil, Vita Brawley, Meenakshi Hegde, Kevin Bielamowicz, Mamta Kalra, Daniel Landi, Catherine Robertson et al.

J Clin Oncol 35, 2017 (suppl; abstr 6047) Presented on June 5th at the 2017 American Society of Clinical Oncology Annual Meeting, Chicago, IL

Cellular immune biomarkers to prognosticate for survival to adoptive T-cell therapy in advanced nasopharyngeal cancer

View Citation

Toh, Han Chong, Richard Hopkins, Qian Ting Ching, Veonice Bijin AU, Lynn Xue WU, Whay-Kuang Chia, Bernett Lee et al.

Hum Gene Ther. 2017 May;28(5):437-448. doi: 10.1089/hum.2016.025. Epub 2016 Aug 16.

Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors Results in Th1 Polarization and Potent Antitumor Activity

View Citation

Li, Wenpeng, Linjie Guo, Purva Rathi, Ekaterina Marinova, Xiuhua Gao, Meng-Feng Wu, Hao Liu et al.

Cancer Res. 2017 Apr 15;77(8):2040-2051. doi: 10.1158/0008-5472.CAN-16-1577. Epub 2017 Feb 24

Armed Oncolytic Adenovirus-Expressing PD-L1 Mini-Body Enhances Antitumor Effects of Chimeric Antigen Receptor T Cells in Solid Tumors

View Citation

Tanoue, Kiyonori, Amanda Rosewell Shaw, Norihiro Watanabe, Caroline Porter, Bhakti Rana, Stephen Gottschalk, Malcolm Brenner, and Masataka Suzuki.

Mol Ther. 2017 Apr 5;25(4):836-838. doi: 10.1016/j.ymthe.2017.03.005. Epub 2017 Mar 18

Partners in Crime: Combining Oncolytic Viroimmunotherapy with Other Therapies

View Citation

Suzuki, Masataka

Mol Ther. 2014 Jan;22(1):132-9. doi: 10.1038/mt.2013.242. Epub 2013 Oct 17.

Adoptive T-cell transfer and chemotherapy in the first-line treatment of metastatic and/or locally recurrent nasopharyngeal carcinoma

View Citation

Chia, Whay-Kuang, Marissa Teo, Who-Whong Wang, Bernett Lee, Soo-Fan Ang, Wai-Meng Tai, Chit-Lai Chee et al.

J Immunother. 2013 Jan;36(1):66-76. doi: 10.1097/CJI.0b013e318279652e.

Human papillomavirus type 16 E6/E7-specific cytotoxic T lymphocytes for adoptive immunotherapy of HPV-associated malignancies

View Citation

Ramos, Carlos A., Neeharika Narala, Gayatri M. Vyas, Ann M. Leen, Ulrike Gerdemann, Erich M. Sturgis, Matthew L. Anderson et al.

J Immunother. 2010 Nov-Dec;33(9):983-90. doi: 10.1097/CJI.0b013e3181f3cbf4.

Adoptive transfer of EBV-specific T cells results in sustained clinical responses in patients with locoregional nasopharyngeal carcinoma

View Citation

Louis, Chrystal U., Karin Straathof, Catherine M. Bollard, Sravya Ennamuri, Claudia Gerken, Teresita T. Lopez, M. Helen Huls et al.

Cytotherapy. 2010 Oct;12(6):743-9. doi: 10.3109/14653241003709686

Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience

View Citation

Cruz, Conrad Russell, Patrick J. Hanley, Hao Liu, Vicky Torrano, Yu-Feng Lin, James A. Arce, Stephen Gottschalk et al.

Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.

Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients

View Citation

Heslop, Helen E., Karen S. Slobod, Martin A. Pule, Gregory A. Hale, Alexandra Rousseau, Colton A. Smith, Catherine M. Bollard et al.

Blood. 2005 Mar 1;105(5):1898-904. Epub 2004 Nov 12.

Treatment of nasopharyngeal carcinoma with Epstein-Barr virus–specific T lymphocytes

View Citation

Straathof, Karin CM, Catherine M. Bollard, Uday Popat, M. Helen Huls, Teresita Lopez, M. Craig Morriss, Mary V. Gresik et al.